A Phase 3 interventional study of Roflumilast and Placebo in COPD, sponsored by AstraZeneca. Completed at 15 sites in 3 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-02-01.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 1 under way, none of them phase 3. Roflumilast · Pulmonary Disease, Chronic Obstructive.
Among the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, this one is the 12th largest by enrollment, is one of 5 that started in 2011, is one of 16 in phase 3, and was the 12th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →1 of the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive is open now. Recruiting first, the newest first:
Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 17 · Phase 4 8
First in 2003; this study’s year is marked. 5 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 626 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 154 across the 32 interventional studies. Of the 30 that completed or were terminated, 17 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 32 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca: 14 open now, 15 under way, 4 of them phase 3. Of 264 finished, 127 (48%) have results posted.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 52nd largest by enrollment of the 194 interventional ones that give a count, is one of 28 that started in 2011, is one of 76 in phase 3, and was the 90th registered.
AstraZeneca’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 1999.
1 of the studies testing roflumilast in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07795086Sidra AzizComparative Effectiveness of Roflumilast and Azithromycin in Reducing Exacerbations in Severe Chronic Obstructive Pulmonary Disease ( COPD ) Patients With Chronic Bronchitis Phenotype | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 284 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
The aim of this trial is to determine the efficacy, safety and tolerability of 500 µg Roflumilast tablets once daily in patients with COPD in China, Hong Kong, and Singapore.
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Roflumilast 500 μg, tablet, oral, once daily for up to 24 weeks.
Drug: Roflumilast · Drug: Salbutamol
Placebo to roflumilast, tablet, oral, once daily for up to 24 weeks.
Drug: Placebo · Drug: Salbutamol
Roflumilast tablets
Placebo tablets
Salbutamol (given by MDI and spacer) used as rescue medication on an ass needed basis throughout the trial, and was used for post-bronchodilator spirometry tests at all study visits.
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)
FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value of pre-bronchodilator FEV1, time and a treatment-by-time interaction as independent variables.
Time frame: Baseline to Week 24
Change From Baseline in Post-bronchodilator FEV1
FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value of post-bronchodilator FEV1, time and a treatment-by-time interaction as independent variables.
Time frame: Baseline to Week 24
Change From Baseline in Pre-bronchodilator Forced Vital Capacity (FVC)
Vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.
Time frame: Baseline to Week 24
Change From Baseline in Post-bronchodilator Forced Vital Capacity (FVC)
Vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.
Time frame: Baseline to Week 24
Change From Baseline in Pre-bronchodilator Forced Expiratory Flow 25-75%
Forced expiratory flow 25-75% (FEF25-75%) is the flow (or speed) of air coming out of the lung during the middle half of a forced expiration. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.
Time frame: Baseline to Week 24
Change From Baseline in Post-bronchodilator Forced Expiratory Flow 25-75%
Forced expiratory flow 25-75% (FEF25-75%) is the flow (or speed) of air coming out of the lung during the middle half of a forced expiration. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.
Time frame: Baseline to Week 24
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Three Seconds (FEV3)
FEV3 is the amount of air which can be forcibly exhaled from the lungs in the first three seconds of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value of pre-bronchodilator FEV3, time and a treatment-by-time interaction as independent variables.
Time frame: Baseline to Week 24
Change From Baseline in Post-bronchodilator Forced Expiratory Volume in First Three Seconds (FEV3)
FEV3 is the amount of air which can be forcibly exhaled from the lungs in the first three seconds of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value of post-bronchodilator FEV3, time and a treatment-by-time interaction as independent variables.
Time frame: Baseline to Week 24
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Six Seconds (FEV6)
FEV6 is the amount of air which can be forcibly exhaled from the lungs in the first six seconds of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value of pre-bronchodilator FEV6, time and a treatment-by-time interaction as independent variables.
Time frame: Baseline to Week 24
Change From Baseline in Post-bronchodilator Forced Expiratory Volume in First Six Seconds (FEV6)
FEV6 is the amount of air which can be forcibly exhaled from the lungs in the first three seconds of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value of post-bronchodilator FEV6, time and a treatment-by-time interaction as independent variables.
Time frame: Baseline to Week 24
Change From Baseline in Pre-bronchodilator Peak Expiratory Flow Rate (PEF)
PEF is the maximal flow (or speed) achieved during the maximally forced expiration initiated at full inspiration. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.
Time frame: Baseline to Week 24
Change From Baseline in Post-bronchodilator Peak Expiratory Flow Rate (PEF)
PEF is the maximal flow (or speed) achieved during the maximally forced expiration initiated at full inspiration. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.
Time frame: Baseline to Week 24
Change From Baseline in Pre-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Vital Capacity
The FEV1/FVC ratio represents the percentage of vital capacity expelled from the lungs during the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication.
Time frame: Baseline and Week 24
Change From Baseline in Post-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Vital Capacity
The FEV1/FVC ratio represents the percentage of vital capacity expelled from the lungs during the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol.
Time frame: Baseline and Week 24
Change From Baseline in Pre-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Expiratory Volume After 6 Seconds
The FEV1/FEV6 ratio represents the percentage of the volume of air expired in the first six seconds that is expelled from the lungs during the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication.
Time frame: Baseline and Week 24
Change From Baseline in Post-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Expiratory Volume After 6 Seconds
The FEV1/FEV6 ratio represents the percentage of the volume of air expired in the first six seconds that is expelled from the lungs during the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol.
Time frame: Baseline and Week 24
Change From Baseline in COPD Symptom Scores
Symptoms of chronic bronchitis with respect to cough and sputum production were assessed daily by the patient and recorded in a diary. Symptoms were assessed on a 4-point scale as follows: Cough: 0: no cough; 1: mild cough (at some time during the day); 2: moderate cough (regularly during the day); 3: severe cough (never free of cough or feeling free of need to cough). Sputum production: 0: no sputum production (unnoticeable); 1: mild sputum production (noticeable as a problem); 2: moderate sputum production (frequent inconvenience); 3: severe sputum production (constant problem). Change from Baseline is reported for cough and sputum separately, and for the sum of the 2 scores (range 0 - 6). Least squares means (LSM) are from a repeated measures ANCOVA model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.
Time frame: Baseline to Week 24
Change From Baseline in Use of Rescue Medication
Salbutamol (given by metered dose inhaler and spacer) was used as rescue medication according to the individual needs of a patient. Each use was documented in the patient's paper diary. Least squares means (LSM) are from a repeated measures ANCOVA model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.
Time frame: Baseline to Week 24
Transition Dyspnoea Index (TDI) Total Score at Week 24
The TDI is a recognized questionnaire to measure dyspnoea (shortness of breath) in patients with COPD. Questions from the TDI were used to assess the 3 components: "change in functional impairment", "change in magnitude of task" and "change in magnitude of effort". Transitions or changes from baseline are rated from -3 (major deterioration) to +3 (major improvement), and summed to give a total score ranging from -9 to +9. Least squares means (LSM) are from a repeated measures ANCOVA model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.
Time frame: Baseline to Week 24
Percentage of Participants With Moderate or Severe COPD Exacerbations
A COPD exacerbation is an event characterised by a worsening in the patient's baseline dyspnoea, or cough and/or sputum beyond day-to-day variability sufficient to warrant a change in management, and may be accompanied by increased wheeze, chest tightness, purulent sputum and symptoms of cold and/or fatigue. COPD exacerbations were categorized as follows: - Severe: Requiring hospitalization and/or leading to death; - Moderate: Requiring oral or parenteral glucocorticosteroid therapy.
Time frame: 24 weeks
Mean Rate of Moderate or Severe COPD Exacerbations Per Patient Per Year
The mean rate of COPD exacerbations per patient per year rate = (number of exacerbations per treatment group/time to study withdrawal per treatment group) \* 365. COPD exacerbations were categorized as follows: - Severe: Requiring hospitalization and/or leading to death; - Moderate: Requiring oral or parenteral glucocorticosteroid therapy.
Time frame: 24 weeks
Time to Onset of First Moderate or Severe COPD Exacerbation
Time to onset of a COPD exacerbation is defined as onset date of COPD exacerbation - date of first intake of study drug + 1 day. COPD exacerbations were categorized as follows: - Severe: Requiring hospitalization and/or leading to death; - Moderate: Requiring oral or parenteral glucocorticosteroid therapy.
Time frame: 24 weeks
Time to Onset of Second Moderate or Severe COPD Exacerbation
Time to onset of a COPD exacerbation is defined as onset date of COPD exacerbation - date of first intake of study drug + 1 day. At least 10 days between the stop date of an exacerbation and the start date of the following exacerbation was required for these to be be considered as two separate COPD exacerbations. COPD exacerbations were categorized as follows: - Severe: Requiring hospitalization and/or leading to death; - Moderate: Requiring oral or parenteral glucocorticosteroid therapy.
Time frame: 24 weeks
Number of Participants With Adverse Events
An adverse event (AE) is any untoward medical occurrence in a clinical trial participant regardless of causal relationship to study drug and regardless whether study drug has been administered. A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. A non-serious AE is any AE that does not meet the criteria above. Each AE was assessed by the Investigator as either 'related' or 'not related' to study drug.
Time frame: 24 weeks
Participants took part in the study at 43 investigative sites in mainland China, Hong Kong and Singapore from 04 Mar 2011 to 16 May 2012.
| Milestone | Roflumilast | Placebo |
|---|---|---|
| Started | 313 | 313 |
| Safety set | 315 | 311 |
| Completed | 246 | 263 |
| Not completed | 67 | 50 |
FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value of pre-bronchodilator FEV1, time and a treatment-by-time interaction as independent variables.
| liters | Roflumilast | Placebo |
|---|---|---|
| Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) | 0.049 ± 0.009 | -0.022 ± 0.009 |
FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value of post-bronchodilator FEV1, time and a treatment-by-time interaction as independent variables.
| liters | Roflumilast | Placebo |
|---|---|---|
| Change From Baseline in Post-bronchodilator FEV1 | 0.045 ± 0.009 | -0.023 ± 0.009 |
Vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.
| liters | Roflumilast | Placebo |
|---|---|---|
| Change From Baseline in Pre-bronchodilator Forced Vital Capacity (FVC) | 0.100 ± 0.017 | -0.009 ± 0.017 |
Vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.
| liters | Roflumilast | Placebo |
|---|---|---|
| Change From Baseline in Post-bronchodilator Forced Vital Capacity (FVC) | 0.094 ± 0.017 | -0.007 ± 0.016 |
Forced expiratory flow 25-75% (FEF25-75%) is the flow (or speed) of air coming out of the lung during the middle half of a forced expiration. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.
| liters/second | Roflumilast | Placebo |
|---|---|---|
| Change From Baseline in Pre-bronchodilator Forced Expiratory Flow 25-75% | 0.023 ± 0.005 | -0.010 ± 0.005 |
Forced expiratory flow 25-75% (FEF25-75%) is the flow (or speed) of air coming out of the lung during the middle half of a forced expiration. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.
| liters/second | Roflumilast | Placebo |
|---|---|---|
| Change From Baseline in Post-bronchodilator Forced Expiratory Flow 25-75% | 0.022 ± 0.005 | -0.008 ± 0.005 |
FEV3 is the amount of air which can be forcibly exhaled from the lungs in the first three seconds of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value of pre-bronchodilator FEV3, time and a treatment-by-time interaction as independent variables.
| liters | Roflumilast | Placebo |
|---|---|---|
| Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Three Seconds (FEV3) | 0.072 ± 0.012 | -0.030 ± 0.012 |
FEV3 is the amount of air which can be forcibly exhaled from the lungs in the first three seconds of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value of post-bronchodilator FEV3, time and a treatment-by-time interaction as independent variables.
| liters | Roflumilast | Placebo |
|---|---|---|
| Change From Baseline in Post-bronchodilator Forced Expiratory Volume in First Three Seconds (FEV3) | 0.064 ± 0.012 | -0.030 ± 0.011 |
FEV6 is the amount of air which can be forcibly exhaled from the lungs in the first six seconds of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value of pre-bronchodilator FEV6, time and a treatment-by-time interaction as independent variables.
| liters | Roflumilast | Placebo |
|---|---|---|
| Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Six Seconds (FEV6) | 0.084 ± 0.014 | -0.031 ± 0.014 |
FEV6 is the amount of air which can be forcibly exhaled from the lungs in the first three seconds of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value of post-bronchodilator FEV6, time and a treatment-by-time interaction as independent variables.
| liters | Roflumilast | Placebo |
|---|---|---|
| Change From Baseline in Post-bronchodilator Forced Expiratory Volume in First Six Seconds (FEV6) | 0.078 ± 0.013 | -0.032 ± 0.013 |
PEF is the maximal flow (or speed) achieved during the maximally forced expiration initiated at full inspiration. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.
| liters/minute | Roflumilast | Placebo |
|---|---|---|
| Change From Baseline in Pre-bronchodilator Peak Expiratory Flow Rate (PEF) | 0.096 ± 0.027 | -0.036 ± 0.026 |
PEF is the maximal flow (or speed) achieved during the maximally forced expiration initiated at full inspiration. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.
| liters/minute | Roflumilast | Placebo |
|---|---|---|
| Change From Baseline in Post-bronchodilator Peak Expiratory Flow Rate (PEF) | 0.099 ± 0.027 | -0.030 ± 0.027 |
The FEV1/FVC ratio represents the percentage of vital capacity expelled from the lungs during the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication.
| percent FEV1/FVC | Roflumilast | Placebo |
|---|---|---|
| Change From Baseline in Pre-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Vital Capacity | -0.570 ± 4.5667 | -1.370 ± 4.9968 |
The FEV1/FVC ratio represents the percentage of vital capacity expelled from the lungs during the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol.
| percent FEV1/FVC | Roflumilast | Placebo |
|---|---|---|
| Change From Baseline in Post-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Vital Capacity | -0.320 ± 4.5400 | -0.940 ± 5.1677 |
The FEV1/FEV6 ratio represents the percentage of the volume of air expired in the first six seconds that is expelled from the lungs during the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication.
| percentage of FEV1/FEV6 | Roflumilast | Placebo |
|---|---|---|
| Change From Baseline in Pre-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Expiratory Volume After 6 Seconds | -0.210 ± 3.9213 | -0.950 ± 3.9173 |
The FEV1/FEV6 ratio represents the percentage of the volume of air expired in the first six seconds that is expelled from the lungs during the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol.
| percentage of FEV1/FEV6 | Roflumilast | Placebo |
|---|---|---|
| Change From Baseline in Post-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Expiratory Volume After 6 Seconds | -0.340 ± 3.7240 | -0.420 ± 4.1957 |
Symptoms of chronic bronchitis with respect to cough and sputum production were assessed daily by the patient and recorded in a diary. Symptoms were assessed on a 4-point scale as follows: Cough: 0: no cough; 1: mild cough (at some time during the day); 2: moderate cough (regularly during the day); 3: severe cough (never free of cough or feeling free of need to cough). Sputum production: 0: no sputum production (unnoticeable); 1: mild sputum production (noticeable as a problem); 2: moderate sputum production (frequent inconvenience); 3: severe sputum production (constant problem). Change from Baseline is reported for cough and sputum separately, and for the sum of the 2 scores (range 0 - 6). Least squares means (LSM) are from a repeated measures ANCOVA model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.
| units on a scale | Roflumilast | Placebo |
|---|---|---|
| Score Sum (n=282, 296) | 0.013 ± 0.054 | 0.064 ± 0.053 |
| Cough (n=284, 299) | -0.019 ± 0.029 | 0.036 ± 0.028 |
| Sputum (n=284, 296) | 0.035 ± 0.030 | 0.037 ± 0.029 |
Salbutamol (given by metered dose inhaler and spacer) was used as rescue medication according to the individual needs of a patient. Each use was documented in the patient's paper diary. Least squares means (LSM) are from a repeated measures ANCOVA model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.
| puffs/day | Roflumilast | Placebo |
|---|---|---|
| Change From Baseline in Use of Rescue Medication | -0.485 ± 0.134 | -0.518 ± 0.131 |
The TDI is a recognized questionnaire to measure dyspnoea (shortness of breath) in patients with COPD. Questions from the TDI were used to assess the 3 components: "change in functional impairment", "change in magnitude of task" and "change in magnitude of effort". Transitions or changes from baseline are rated from -3 (major deterioration) to +3 (major improvement), and summed to give a total score ranging from -9 to +9. Least squares means (LSM) are from a repeated measures ANCOVA model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.
| units on a scale | Roflumilast | Placebo |
|---|---|---|
| Transition Dyspnoea Index (TDI) Total Score at Week 24 | 1.335 ± 0.124 | 1.396 ± 0.122 |
A COPD exacerbation is an event characterised by a worsening in the patient's baseline dyspnoea, or cough and/or sputum beyond day-to-day variability sufficient to warrant a change in management, and may be accompanied by increased wheeze, chest tightness, purulent sputum and symptoms of cold and/or fatigue. COPD exacerbations were categorized as follows: - Severe: Requiring hospitalization and/or leading to death; - Moderate: Requiring oral or parenteral glucocorticosteroid therapy.
| percentage of participants | Roflumilast | Placebo |
|---|---|---|
| No exacerbations | 81.8 | 84.7 |
| One exacerbation | 15.0 | 12.8 |
| Two exacerbations | 2.6 | 1.9 |
| Three exacerbations | 0.6 | 0.6 |
The mean rate of COPD exacerbations per patient per year rate = (number of exacerbations per treatment group/time to study withdrawal per treatment group) \* 365. COPD exacerbations were categorized as follows: - Severe: Requiring hospitalization and/or leading to death; - Moderate: Requiring oral or parenteral glucocorticosteroid therapy.
| exacerbations per patient per year | Roflumilast | Placebo |
|---|---|---|
| Mean Rate of Moderate or Severe COPD Exacerbations Per Patient Per Year | 0.55 | 0.44 |
Time to onset of a COPD exacerbation is defined as onset date of COPD exacerbation - date of first intake of study drug + 1 day. COPD exacerbations were categorized as follows: - Severe: Requiring hospitalization and/or leading to death; - Moderate: Requiring oral or parenteral glucocorticosteroid therapy.
| days | Roflumilast | Placebo |
|---|---|---|
| Time to Onset of First Moderate or Severe COPD Exacerbation | 67.0 (3 to 165) | 86.0 (2 to 168) |
Time to onset of a COPD exacerbation is defined as onset date of COPD exacerbation - date of first intake of study drug + 1 day. At least 10 days between the stop date of an exacerbation and the start date of the following exacerbation was required for these to be be considered as two separate COPD exacerbations. COPD exacerbations were categorized as follows: - Severe: Requiring hospitalization and/or leading to death; - Moderate: Requiring oral or parenteral glucocorticosteroid therapy.
| days | Roflumilast | Placebo |
|---|---|---|
| Time to Onset of Second Moderate or Severe COPD Exacerbation | 119.5 (50 to 166) | 117.0 (71 to 163) |
An adverse event (AE) is any untoward medical occurrence in a clinical trial participant regardless of causal relationship to study drug and regardless whether study drug has been administered. A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. A non-serious AE is any AE that does not meet the criteria above. Each AE was assessed by the Investigator as either 'related' or 'not related' to study drug.
| participants | Roflumilast | Placebo |
|---|---|---|
| All AEs | 213 | 196 |
| Non-serious AEs | 189 | 172 |
| Serious AEs (including death) | 62 | 48 |
| Death | 2 | 2 |
| Serious AEs not including death | 60 | 46 |
| AEs with suggested relationship to trial treatment | 65 | 18 |
| AEs leading to withdrawal from the trial | 15 | 2 |
| AEs not recovered at trial termination | 54 | 45 |
| AEs with changes in concomitant medication | 164 | 155 |
Collected over 24 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Roflumilast | — | 62/315 (19.7%) | 143/315 (45.4%) |
| Placebo | — | 48/311 (15.4%) | 133/311 (42.8%) |
| Event | Roflumilast | Placebo |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 44/315 | 39/311 |
| Colonic polypGastrointestinal disorders | 1/315 | 2/311 |
| PneumoniaInfections and infestations | 2/315 | 2/311 |
| Acute myocardial infarctionCardiac disorders | 2/315 | 0/311 |
| Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/315 | 0/311 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 2/315 | 1/311 |
| Angina unstableCardiac disorders | 1/315 | 1/311 |
| Cardiac failureCardiac disorders | 1/315 | 1/311 |
| HydroceleCongenital, familial and genetic disorders | 0/315 | 1/311 |
| AppendicitisInfections and infestations | 1/315 | 1/311 |
| Event | Roflumilast | Placebo |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 90/315 | 89/311 |
| NasopharyngitisInfections and infestations | 28/315 | 45/311 |
| DiarrhoeaGastrointestinal disorders | 21/315 | 3/311 |
| Decreased appetiteMetabolism and nutrition disorders | 19/315 | 2/311 |
| Upper respiratory tract infectionInfections and infestations | 17/315 | 18/311 |
| Age, Continuous(Years) | Roflumilast | Placebo | Total |
|---|---|---|---|
| Mean | 64.2 ± 8.76 | 64.0 ± 8.27 | 64.1 ± 8.51 |
| Gender(Participants) | Roflumilast | Placebo | Total |
|---|---|---|---|
| Female | 30 | 27 | 57 |
| Male | 283 | 286 | 569 |
| Race (NIH/OMB)(Participants) | Roflumilast | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 313 | 313 | 626 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Height(cm) | Roflumilast | Placebo | Total |
|---|---|---|---|
| Mean | 166.2 ± 7.27 | 165.9 ± 7.12 | 166.1 ± 7.20 |
| Weight(kg) | Roflumilast | Placebo | Total |
|---|---|---|---|
| Mean | 60.4 ± 11.00 | 61.8 ± 10.54 | 61.1 ± 10.78 |
| Body Mass Index (BMI)(kg/m^2) | Roflumilast | Placebo | Total |
|---|---|---|---|
| Mean | 21.8 ± 3.42 | 22.4 ± 3.43 | 22.1 ± 3.44 |
| Chronic obstructive pulmonary disease (COPD) severity(Participants) | Roflumilast | Placebo | Total |
|---|---|---|---|
| Mild | 1 | 1 | 2 |
| Moderate | 28 | 16 | 44 |
| Severe | 196 | 204 | 400 |
| Very severe | 88 | 92 | 180 |
| COPD disease characteristics(Participants) | Roflumilast | Placebo | Total |
|---|---|---|---|
| Predominantly chronic bronchitis | 56 | 61 | 117 |
| Combined emphysema and chronic bronchitis | 217 | 216 | 433 |
| Predominantly emphysema | 40 | 36 | 76 |
9 further baseline measures are reported on the registry.
The record gives a start of Mar 2011, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2013, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Roflumilast
Pulmonary Disease, Chronic Obstructive →